[HTML][HTML] Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab

M Shi, F Chu, F Zhu, J Zhu - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …

Aβ-oligomers: A potential therapeutic target for Alzheimer's disease

S Ghosh, R Ali, S Verma - International Journal of Biological …, 2023 - Elsevier
The cascade of amyloid formation relates to multiple complex events at the molecular level.
Previous research has established amyloid plaque deposition as the leading cause of …

[HTML][HTML] Trial of solanezumab in preclinical Alzheimer's disease

RA Sperling, MC Donohue, R Raman… - … England Journal of …, 2023 - Mass Medical Soc
Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

[HTML][HTML] Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

SF Ackley, SC Zimmerman, WD Brenowitz… - Bmj, 2021 - bmj.com
Objective To evaluate trials of drugs that target amyloid to determine whether reductions in
amyloid levels are likely to improve cognition. Design Instrumental variable meta-analysis …

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

PL McGeer, EG McGeer - Acta neuropathologica, 2013 - Springer
The amyloid cascade hypothesis is widely accepted as the centerpiece of Alzheimer
disease (AD) pathogenesis. It proposes that abnormal production of beta amyloid protein …

[HTML][HTML] Circulating miRNA biomarkers for Alzheimer's disease

P Kumar, Z Dezso, C MacKenzie, J Oestreicher… - PloS one, 2013 - journals.plos.org
A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is
required to select optimal patient groups in clinical trials, monitor disease progression and …

[HTML][HTML] A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

E Karran, J Hardy - Annals of neurology, 2014 - ncbi.nlm.nih.gov
In 1906, Alois Alzheimer described the neuropathology of the disease that was to bear his
name. 1 Subsequently, our understanding of Alzheimer disease (AD) has grown …

Terminally modified RNA

T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Modified polynucleotides for the production of biologics and proteins associated with human disease

S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Modified polynucleotides for the production of secreted proteins

T Chakraborty, A De Fougerolles - US Patent 9,192,651, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …